Francis Knuettel II - 01 Jul 2025 Form 4 Insider Report for Pelthos Therapeutics Inc. (CHRO)

Reporting relationship: Chief Financial Officer
Issuer ticker: CHRO
Reported as of: 01 Jul 2025
Net transaction value: +$100,000
SEC form: 4
Accepted by SEC: 03 Jul 2025, 21:04:18 UTC
Prior SEC filing: 02 Jun 2025
Next SEC filing: 01 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Francis Knuettel II

Key filing fact

Francis Knuettel II filed Form 4 for Pelthos Therapeutics Inc. (CHRO) on 03 Jul 2025.

Key facts

This page summarizes Francis Knuettel II's Form 4 filing for Pelthos Therapeutics Inc. (CHRO).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 03 Jul 2025, 21:04.

Change

Previous filing in this sequence was filed on 02 Jun 2025.
Current net transaction value: +$100,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001433316 Primary reporting owner

Francis Knuettel II

Relationship: Chief Financial Officer
Address: C/O PELTHOS THERAPEUTICS INC., 4020 STIRRUP CREEK DRIVE, DURHAM
Signature: /s/ Francis Knuettel II
Signature date: 03 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PTHS transaction

Common Stock

Conversion of derivative security

Transaction value: $100,000
Shares: +10,000
Change %
Price: $10.00
Shares after: 10,000
Date: 01 Jul 2025
Ownership: By Camden Capital LLC
Footnotes: F1, F2

PTHS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 12,816
Date: 01 Jul 2025
Ownership: By Lara Knuettel Revocable Trust
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PTHS transaction Derivative

Series A Convertible Preferred Stock

Other

Transaction value: $0
Shares: +10,000
Change %
Price: $0.000000
Shares after: 10,000
Date: 01 Jul 2025
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 10,000
Exercise price: $10.00
Footnotes: F1, F2, F3, F4

PTHS transaction Derivative

Series A Convertible Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -10,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 01 Jul 2025
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 10,000
Exercise price: $10.00
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

Footnote F2

Francis Knuettel II is the manager of Camden Capital LLC ("Camden") and the co-trustee of the Lara Knuettel Revocable Trust (the "Trust"). By virtue of these relationships, Mr. Knuettel may be deemed to beneficially own the shares of Common Stock held of record by each of Camden and the Trust. Mr. Knuettel disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

Footnote F3

The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

Footnote F4

Acquired in connection with cancellation of promissory note.